Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?

Lignende værker

• Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?
  af: Gridelli, Cesare, et al.
  Udgivet: (2019)
• Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
  af: Mienko, Fiona, et al.
  Udgivet: (2020)
• First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
  af: Zhou, Yixin, et al.
  Udgivet: (2019)
• KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?
  af: Pacheco, Jose M.
  Udgivet: (2019)
• Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
  af: Alessi, Joao V, et al.
  Udgivet: (2020)